Vorapaxar did not reduce the first occurrence of the primary endpoint of CVD , MI , stroke , revascularization , or rehospitalization for recurrent ischemia , but reduced the secondary composite endpoint of CVD , MI , or stroke ( 14.7 % vorapaxar vs. 16.4 % placebo ; hazard ratio [ HR ] , 0.89 ; 95 % confidence interval [ CI ] , 0.81 to 0.98 ; P = 0.02 ; number needed to treat [ NNT ] , 81 ) .